Teladoc Health Grants Stock Award to New Employee
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Source: Newsfilter
- Stock Award Program: On July 1, 2026, Teladoc Health granted 50,000 restricted stock units to new Head of Product David Packles, aimed at attracting and retaining key talent to enhance the company's leadership in virtual care.
- Vesting Conditions: The stock units will vest based on continued service, with one-third vesting on the first anniversary and the remainder vesting quarterly over the next two years, aligning employee interests with long-term company goals.
- Compliance Review: This stock award was approved by Teladoc Health's Compensation Committee and granted under NYSE Rule 303A.08, ensuring compliance and transparency in the company's incentive practices.
- Company Background: Teladoc Health is the global leader in virtual care, collaborating with health plans, employers, and providers to drive better health outcomes and lower costs, further solidifying its market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TDOC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TDOC
Wall Street analysts forecast TDOC stock price to fall
15 Analyst Rating
3 Buy
12 Hold
0 Sell
Hold
Current: 9.290
Low
7.50
Averages
8.91
High
12.00
Current: 9.290
Low
7.50
Averages
8.91
High
12.00
About TDOC
Teladoc Health, Inc. provides virtual healthcare services. Its segments include Teladoc Health Integrated Care (Integrated Care) and BetterHelp. Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed on a B2B basis. BetterHelp segment includes direct-to-consumer mental health platform. The online counseling and therapy services are provided via its network of over 35,000 licensed clinicians leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs. Its Telecare brand is a tech-enabled provider of specialist and allied health care via virtual delivery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Choices: Hims & Hers vs. Teladoc
- User Growth Surge: Hims & Hers Health boasts nearly 2.6 million subscribers as of Q1 2026, indicating significant market traction for its direct-to-consumer wellness solutions, thereby enhancing its competitive position in the digital health sector.
- Financial Performance Comparison: Hims & Hers reported nearly $2.3 billion in revenue for FY 2025, reflecting a robust 59% year-over-year growth, while Teladoc's revenue of approximately $2.5 billion saw a slight decline of 1.5%, suggesting Hims & Hers may attract investors seeking rapid growth.
- Market Risks and Regulatory Pressures: Hims & Hers faces regulatory scrutiny from the FDA regarding compounded GLP-1s and potential DOJ investigations, which could hinder its growth trajectory, whereas Teladoc's heavy customer concentration poses risks of significant financial impact from losing major clients.
- Valuation and Investment Strategy: Hims & Hers carries a premium valuation due to its growth potential, raising investor concerns over regulatory issues, while Teladoc's lower P/S ratio and turnaround strategy appeal to those looking for opportunities in undervalued stocks.
See More
Investment Comparison Between Hims & Hers and Teladoc
- User Base Growth: As of Q1 2026, Hims & Hers boasts approximately 2.6 million subscribers, reflecting significant growth and indicating strong market acceptance of its direct-to-consumer health solutions, thereby enhancing its competitive position in the digital health sector.
- Financial Performance Comparison: Hims & Hers reported nearly $2.3 billion in revenue for FY 2025, representing a robust 59% year-over-year growth, while Teladoc's revenue of $2.5 billion saw a slight decline of 1.5%, highlighting Hims & Hers' stronger performance in profitability and market demand.
- Acquisition and Financing Dynamics: Hims & Hers is scaling operations through the acquisition of Eucalyptus and has secured a $400 million receivables facility with JPMorgan Chase, which will support its pharmacy operations and further solidify its market position.
- Risks and Challenges: Hims & Hers faces potential FDA restrictions on certain ingredients and investigations by the DOJ and HHS, while Teladoc's heavy reliance on a few large clients poses a risk to its financial stability, illustrating the significant strategic differences between the two companies.
See More
Surge in Options Volume for ANI and Teladoc
- ANI Options Volume: Today, ANI Pharmaceuticals has seen options volume of 3,048 contracts, representing approximately 304,800 shares, which is a significant 88.9% of its average daily trading volume of 342,900 shares over the past month.
- High Strike Interest: Notably, the $85 strike call option expiring on October 16, 2026, has traded 3,011 contracts today, equating to about 301,100 shares, indicating strong market interest at this price point.
- Teladoc Options Activity: Teladoc Health's options volume stands at 35,738 contracts, approximately 3.6 million shares, reflecting a robust 82.2% of its average daily trading volume of 4.4 million shares over the past month.
- Key Contract Insights: The $10 strike call option expiring on July 10, 2026, has seen 21,194 contracts traded today, representing around 2.1 million shares, showcasing investor optimism regarding Teladoc's future performance.
See More
Teladoc Health Grants Stock Award to New Employee
- Stock Award Program: On July 1, 2026, Teladoc Health granted 50,000 restricted stock units to new Head of Product David Packles, aimed at attracting and retaining key talent to enhance the company's leadership in virtual care.
- Vesting Conditions: The stock units will vest based on continued service, with one-third vesting on the first anniversary and the remainder vesting quarterly over the next two years, aligning employee interests with long-term company goals.
- Compliance Review: This stock award was approved by Teladoc Health's Compensation Committee and granted under NYSE Rule 303A.08, ensuring compliance and transparency in the company's incentive practices.
- Company Background: Teladoc Health is the global leader in virtual care, collaborating with health plans, employers, and providers to drive better health outcomes and lower costs, further solidifying its market position.
See More
Teladoc Health Shares Surge 28% Amid Recovery Efforts
- Stock Price Surge: Teladoc's shares have risen 28% this year, significantly outperforming the S&P 500's 9% increase, indicating market optimism about its recovery potential despite ongoing profitability challenges.
- Revenue Performance: In Q1, Teladoc's revenue declined 2% year-over-year to $613.8 million, with BetterHelp's sales dropping 9%, reflecting growth pressures, yet the market remains hopeful about future developments.
- Insurance Coverage Progress: Teladoc has achieved health insurance coverage for BetterHelp in several states through acquisitions, expecting to reach an annual run rate of at least $125 million by the end of 2026, a significant improvement from $75 million in Q1, indicating progress in enhancing user experience.
- International Expansion and AI Initiatives: Teladoc's international revenue grew 17% year-over-year to $122.3 million, while AI technology is being implemented to reduce administrative tasks, allowing therapists to focus more on patients, which could improve financial performance and stock price in the long run.
See More
Teladoc's Business Shows Improvement Amid Challenges
- Stock Recovery: Teladoc's shares have risen by 28% year-to-date, significantly outperforming the S&P 500's 9% increase, indicating market optimism about its recovery potential despite ongoing profitability challenges.
- Revenue Performance: In Q1, Teladoc's revenue declined by 2% year-over-year to $613.8 million, with its BetterHelp virtual therapy division seeing a 9% drop in sales, highlighting the company's ongoing struggle to regain growth momentum.
- Insurance Coverage Progress: Teladoc has achieved health insurance coverage for BetterHelp in several states through acquisitions, with insured users averaging 20% more therapy sessions than cash-paying patients in their first 90 days, and expects to reach an annual run rate of at least $125 million by the end of 2026, marking a significant improvement.
- International Expansion and AI Initiatives: Teladoc's international revenue grew by 17% year-over-year to $122.3 million, while AI technology has reduced administrative tasks for therapists, allowing more patient focus, although the company still faces complex legal and regulatory challenges in its global expansion efforts.
See More
Investment Choices: Hims & Hers vs. Teladoc
- User Growth Surge: Hims & Hers Health boasts nearly 2.6 million subscribers as of Q1 2026, indicating significant market traction for its direct-to-consumer wellness solutions, thereby enhancing its competitive position in the digital health sector.
- Financial Performance Comparison: Hims & Hers reported nearly $2.3 billion in revenue for FY 2025, reflecting a robust 59% year-over-year growth, while Teladoc's revenue of approximately $2.5 billion saw a slight decline of 1.5%, suggesting Hims & Hers may attract investors seeking rapid growth.
- Market Risks and Regulatory Pressures: Hims & Hers faces regulatory scrutiny from the FDA regarding compounded GLP-1s and potential DOJ investigations, which could hinder its growth trajectory, whereas Teladoc's heavy customer concentration poses risks of significant financial impact from losing major clients.
- Valuation and Investment Strategy: Hims & Hers carries a premium valuation due to its growth potential, raising investor concerns over regulatory issues, while Teladoc's lower P/S ratio and turnaround strategy appeal to those looking for opportunities in undervalued stocks.
See More
Investment Comparison Between Hims & Hers and Teladoc
- User Base Growth: As of Q1 2026, Hims & Hers boasts approximately 2.6 million subscribers, reflecting significant growth and indicating strong market acceptance of its direct-to-consumer health solutions, thereby enhancing its competitive position in the digital health sector.
- Financial Performance Comparison: Hims & Hers reported nearly $2.3 billion in revenue for FY 2025, representing a robust 59% year-over-year growth, while Teladoc's revenue of $2.5 billion saw a slight decline of 1.5%, highlighting Hims & Hers' stronger performance in profitability and market demand.
- Acquisition and Financing Dynamics: Hims & Hers is scaling operations through the acquisition of Eucalyptus and has secured a $400 million receivables facility with JPMorgan Chase, which will support its pharmacy operations and further solidify its market position.
- Risks and Challenges: Hims & Hers faces potential FDA restrictions on certain ingredients and investigations by the DOJ and HHS, while Teladoc's heavy reliance on a few large clients poses a risk to its financial stability, illustrating the significant strategic differences between the two companies.
See More
Surge in Options Volume for ANI and Teladoc
- ANI Options Volume: Today, ANI Pharmaceuticals has seen options volume of 3,048 contracts, representing approximately 304,800 shares, which is a significant 88.9% of its average daily trading volume of 342,900 shares over the past month.
- High Strike Interest: Notably, the $85 strike call option expiring on October 16, 2026, has traded 3,011 contracts today, equating to about 301,100 shares, indicating strong market interest at this price point.
- Teladoc Options Activity: Teladoc Health's options volume stands at 35,738 contracts, approximately 3.6 million shares, reflecting a robust 82.2% of its average daily trading volume of 4.4 million shares over the past month.
- Key Contract Insights: The $10 strike call option expiring on July 10, 2026, has seen 21,194 contracts traded today, representing around 2.1 million shares, showcasing investor optimism regarding Teladoc's future performance.
See More
Teladoc Health Grants Stock Award to New Employee
- Stock Award Program: On July 1, 2026, Teladoc Health granted 50,000 restricted stock units to new Head of Product David Packles, aimed at attracting and retaining key talent to enhance the company's leadership in virtual care.
- Vesting Conditions: The stock units will vest based on continued service, with one-third vesting on the first anniversary and the remainder vesting quarterly over the next two years, aligning employee interests with long-term company goals.
- Compliance Review: This stock award was approved by Teladoc Health's Compensation Committee and granted under NYSE Rule 303A.08, ensuring compliance and transparency in the company's incentive practices.
- Company Background: Teladoc Health is the global leader in virtual care, collaborating with health plans, employers, and providers to drive better health outcomes and lower costs, further solidifying its market position.
See More
Teladoc Health Shares Surge 28% Amid Recovery Efforts
- Stock Price Surge: Teladoc's shares have risen 28% this year, significantly outperforming the S&P 500's 9% increase, indicating market optimism about its recovery potential despite ongoing profitability challenges.
- Revenue Performance: In Q1, Teladoc's revenue declined 2% year-over-year to $613.8 million, with BetterHelp's sales dropping 9%, reflecting growth pressures, yet the market remains hopeful about future developments.
- Insurance Coverage Progress: Teladoc has achieved health insurance coverage for BetterHelp in several states through acquisitions, expecting to reach an annual run rate of at least $125 million by the end of 2026, a significant improvement from $75 million in Q1, indicating progress in enhancing user experience.
- International Expansion and AI Initiatives: Teladoc's international revenue grew 17% year-over-year to $122.3 million, while AI technology is being implemented to reduce administrative tasks, allowing therapists to focus more on patients, which could improve financial performance and stock price in the long run.
See More
Teladoc's Business Shows Improvement Amid Challenges
- Stock Recovery: Teladoc's shares have risen by 28% year-to-date, significantly outperforming the S&P 500's 9% increase, indicating market optimism about its recovery potential despite ongoing profitability challenges.
- Revenue Performance: In Q1, Teladoc's revenue declined by 2% year-over-year to $613.8 million, with its BetterHelp virtual therapy division seeing a 9% drop in sales, highlighting the company's ongoing struggle to regain growth momentum.
- Insurance Coverage Progress: Teladoc has achieved health insurance coverage for BetterHelp in several states through acquisitions, with insured users averaging 20% more therapy sessions than cash-paying patients in their first 90 days, and expects to reach an annual run rate of at least $125 million by the end of 2026, marking a significant improvement.
- International Expansion and AI Initiatives: Teladoc's international revenue grew by 17% year-over-year to $122.3 million, while AI technology has reduced administrative tasks for therapists, allowing more patient focus, although the company still faces complex legal and regulatory challenges in its global expansion efforts.
See More
